You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 284 No. 16, October 25, 2000 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Viral Load in Treatment With Antiretroviral Therapy and Interleukin 2

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In a randomized controlled trial of interleukin 2 (IL-2) in combination with antiretroviral therapy (ART) for human immunodeficiency virus type 1 (HIV-1) infection, Dr Davey and colleagues1 observed a larger decrease in viral load with IL-2 plus ART compared with ART alone (control arm). The authors suggest that IL-2 was responsible for this better control of viral load.

One of the main factors determining viral load decrease and control with ART is compliance. It is possible that patients in the IL-2 plus ART arm were more compliant with ART than patients in the control arm because they might have received more frequent, intense, and specific recommendations on the importance of taking ART combined with IL-2. It also is possible that patients who completed the study were more compliant in the IL-2 plus ART arm than in the control arm because, according to Figure 1, 9 of 39 . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral Therapy: A Randomized Controlled Trial
Richard T. Davey, Jr, Robert L. Murphy, Frank M. Graziano, Stephen L. Boswell, Andrew T. Pavia, Margarita Cancio, Jeffrey P. Nadler, Doreen G. Chaitt, Robin L. Dewar, David K. Sahner, Anne-Marie Duliege, William B. Capra, Wai-Ping Leong, Martin A. Giedlin, H. Clifford Lane, and James O. Kahn
JAMA. 2000;284(2):183-189.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.